How the GLP-1 receptor agonist market could hit $168bn by 2033
In the past few years, there has been a significant increase in the use of GLP-1 receptor agonists as a treatment for Type 2 diabetes and obesity.
In Association With Datwyler
Putting quality first in the pharma supply chain
No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challenges
The next phase for mRNA: Looking beyond COVID-19
Why small particles matter: Manufacturing and micro-material contamination
Five years of FirstLine in the United States
Evaluating the top five sterilisation techniques for parenteral packaging
Reducing interactions between drug packaging and product with film-coated sealing solutions
Overcoming disruptions in the pharmaceutical supply chain
